ENANTA PHARMACEUTICALS, INC Current Assets
ENANTA PHARMACEUTICALS, INC (ENTA) had Current Assets of $203.62 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-12
- 2026-06-30: Assets, Current $203.62M.
- 2026-03-31: Assets, Current $178.41M.
- 2025-12-31: Assets, Current $198.68M.
- 2025-09-30: Assets, Current $204.34M.
| Period end | Assets, Current |
|---|---|
| 2026-06-30 | $203.62M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $178.41M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $198.68M 10-Q · filed 2026-02-11 |
| 2025-09-30 | $204.34M 10-Q · filed 2026-08-12 |
| 2025-06-30 | $222.71M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $242.86M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $268.14M 10-Q · filed 2025-02-12 |
| 2024-09-30 | $299.85M 10-K · filed 2025-11-19 |
| 2024-06-30 | $286.58M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $351.03M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $390.30M 10-Q · filed 2024-02-08 |
| 2023-09-30 | $422.79M 10-K · filed 2024-11-27 |
| 2023-06-30 | $448.46M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $271.14M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $283.70M 10-Q · filed 2023-02-08 |
| 2022-09-30 | $311.71M 10-K · filed 2023-11-22 |
| 2022-06-30 | $313.04M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $341.87M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $326.96M 10-Q · filed 2022-02-10 |
| 2021-09-30 | $319.02M 10-K · filed 2022-11-23 |
| 2021-06-30 | $321.15M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $428.22M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $445.94M 10-Q · filed 2021-02-09 |
| 2020-09-30 | $436.84M 10-K · filed 2021-11-24 |
| 2020-06-30 | $413.38M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $402.71M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $440.51M 10-Q · filed 2020-02-10 |
| 2019-09-30 | $401.85M 10-K · filed 2020-11-25 |
| 2019-06-30 | $451.26M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $423.84M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $423.31M 10-Q · filed 2019-02-08 |
| 2018-09-30 | $380.39M 10-K · filed 2019-11-27 |
| 2018-06-30 | $339.89M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $305.68M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $247.63M 10-Q · filed 2018-02-09 |
| 2017-09-30 | $237.82M 10-K · filed 2018-11-29 |
| 2017-06-30 | $206.12M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $190.59M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $224.06M 10-Q · filed 2017-02-09 |
| 2016-09-30 | $232.16M 10-K · filed 2017-12-11 |
| 2016-06-30 | $241.79M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $242.66M 10-Q · filed 2016-05-10 |
| 2015-12-31 | $209.02M 10-Q · filed 2016-02-09 |
| 2015-09-30 | $170.64M 10-K · filed 2016-12-09 |
| 2015-06-30 | $172.64M 10-Q · filed 2015-08-10 |
| 2015-03-31 | $177.78M 10-Q · filed 2015-05-08 |
| 2014-12-31 | $185.10M 10-Q · filed 2015-02-06 |
| 2014-09-30 | $107.97M 10-K · filed 2015-12-11 |
| 2014-06-30 | $111.68M 10-Q · filed 2014-08-12 |
| 2014-03-31 | $99.35M 10-Q · filed 2014-05-12 |
| 2013-12-31 | $94.38M 10-Q · filed 2014-02-13 |
| 2013-09-30 | $104.71M 10-K · filed 2014-12-11 |
| 2013-06-30 | $97.87M 10-Q · filed 2013-08-12 |
| 2013-03-31 | $111.66M 10-Q · filed 2013-05-15 |
| 2012-09-30 | $47.31M 10-K · filed 2013-12-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |